WO2009044547A1 - 神経細胞死抑制剤 - Google Patents

神経細胞死抑制剤 Download PDF

Info

Publication number
WO2009044547A1
WO2009044547A1 PCT/JP2008/002768 JP2008002768W WO2009044547A1 WO 2009044547 A1 WO2009044547 A1 WO 2009044547A1 JP 2008002768 W JP2008002768 W JP 2008002768W WO 2009044547 A1 WO2009044547 A1 WO 2009044547A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
nerve cell
death inhibitor
inhibitor
disclosed
Prior art date
Application number
PCT/JP2008/002768
Other languages
English (en)
French (fr)
Inventor
Fumiyasu Sato
Yasunobu Yoshinaka
Taro Aoki
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Priority to ES08836702T priority Critical patent/ES2389392T3/es
Priority to JP2009535978A priority patent/JP5399909B2/ja
Priority to DK08836702.4T priority patent/DK2193793T3/da
Priority to CN200880109935A priority patent/CN101815517A/zh
Priority to EP08836702A priority patent/EP2193793B1/en
Priority to PL08836702T priority patent/PL2193793T3/pl
Priority to CA2701397A priority patent/CA2701397C/en
Priority to KR1020107006970A priority patent/KR101503782B1/ko
Priority to US12/676,265 priority patent/US7973053B2/en
Publication of WO2009044547A1 publication Critical patent/WO2009044547A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明は、優れた神経細胞死抑制作用を示す薬剤を提供する。 　本発明は、ピタバスタチン類及びドネペジル又はその塩とを組み合わせてなる神経細胞死抑制剤に関する。
PCT/JP2008/002768 2007-10-03 2008-10-02 神経細胞死抑制剤 WO2009044547A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES08836702T ES2389392T3 (es) 2007-10-03 2008-10-02 Inhibidor de la muerte de las neuronas
JP2009535978A JP5399909B2 (ja) 2007-10-03 2008-10-02 神経細胞死抑制剤
DK08836702.4T DK2193793T3 (da) 2007-10-03 2008-10-02 Nervecelle-døds-inhibitor
CN200880109935A CN101815517A (zh) 2007-10-03 2008-10-02 神经细胞死亡抑制剂
EP08836702A EP2193793B1 (en) 2007-10-03 2008-10-02 Nerve cell death inhibitor
PL08836702T PL2193793T3 (pl) 2007-10-03 2008-10-02 Inhibitor śmierci komórek nerwowych
CA2701397A CA2701397C (en) 2007-10-03 2008-10-02 Nerve cell death inhibitor
KR1020107006970A KR101503782B1 (ko) 2007-10-03 2008-10-02 신경 세포사 억제제
US12/676,265 US7973053B2 (en) 2007-10-03 2008-10-02 Nerve cell death inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-259682 2007-10-03
JP2007259682 2007-10-03

Publications (1)

Publication Number Publication Date
WO2009044547A1 true WO2009044547A1 (ja) 2009-04-09

Family

ID=40525979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002768 WO2009044547A1 (ja) 2007-10-03 2008-10-02 神経細胞死抑制剤

Country Status (13)

Country Link
US (1) US7973053B2 (ja)
EP (1) EP2193793B1 (ja)
JP (1) JP5399909B2 (ja)
KR (1) KR101503782B1 (ja)
CN (1) CN101815517A (ja)
CA (1) CA2701397C (ja)
CY (1) CY1113364T1 (ja)
DK (1) DK2193793T3 (ja)
ES (1) ES2389392T3 (ja)
PL (1) PL2193793T3 (ja)
PT (1) PT2193793E (ja)
TW (1) TWI432195B (ja)
WO (1) WO2009044547A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018000228A1 (zh) 2016-06-29 2018-01-04 北京小米移动软件有限公司 数据传输方法、装置和终端

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
JPH11171861A (ja) 1997-12-12 1999-06-29 Eisai Co Ltd ドネペジルの製造法
JPH11263774A (ja) 1998-01-16 1999-09-28 Eisai Co Ltd ドネペジル誘導体の製造法およびその中間体
WO1999048488A2 (en) 1998-03-23 1999-09-30 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
WO2000028981A2 (en) 1998-11-13 2000-05-25 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
WO2001032161A2 (en) 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
WO2001096311A2 (en) 2000-06-15 2001-12-20 Bristol-Myers Squibb Company Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
WO2002062824A2 (en) 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid ? precursor disorder
WO2005099823A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of alzheimers disease
WO2007088705A1 (ja) 2006-01-31 2007-08-09 Kowa Co., Ltd. 糖尿病治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1492539T3 (da) 2002-04-02 2006-10-30 Janssen Pharmaceutica Nv Statin-terapi til forögelse af kognitiv funktion
BRPI0408491A (pt) * 2003-03-19 2006-04-04 Ares Trading Sa tratamento da doença de alzheimer
JPWO2005063294A1 (ja) 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479151A (en) 1987-06-22 1989-03-24 Eisai Co Ltd Cyclic amine derivative
JPH07252216A (ja) 1987-06-22 1995-10-03 Eisai Co Ltd 環状アミン誘導体
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JPH11171861A (ja) 1997-12-12 1999-06-29 Eisai Co Ltd ドネペジルの製造法
JPH11263774A (ja) 1998-01-16 1999-09-28 Eisai Co Ltd ドネペジル誘導体の製造法およびその中間体
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
WO1999048488A2 (en) 1998-03-23 1999-09-30 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6440387B1 (en) 1998-03-23 2002-08-27 Children's Medical Center Corporation Methods for determining risk of Alzheimer's disease
WO2000028981A2 (en) 1998-11-13 2000-05-25 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
JP2002529500A (ja) * 1998-11-13 2002-09-10 ナイモックス コーポレーション ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
WO2001032161A2 (en) 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
WO2001096311A2 (en) 2000-06-15 2001-12-20 Bristol-Myers Squibb Company Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
WO2002062824A2 (en) 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid ? precursor disorder
WO2005099823A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of alzheimers disease
WO2007088705A1 (ja) 2006-01-31 2007-08-09 Kowa Co., Ltd. 糖尿病治療剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHIE OKI ET AL.: "Ikkasei No Kyoketsu Sunanezumi no Chihatsusei Shinkei Saiboshi ni Taisuru Pitavastatin (HMG-CoA Kangen Koso Sogaiyaku) no Kosanka Sayo", THERAPEUTIC RESEARCH, vol. 26, no. 6, 2005, pages 1277 - 1286 *
KUMAGAI ET AL., J. NEURAL. TRANSM., vol. 111, 2004, pages 1103 - 1120
MIIDA, PHARMACOL. THER., vol. 113, pages 378 - 393
MIIDA, T. ET AL.: "Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects", PHARMACOL THER, vol. 113, no. 2, 2007, pages 378 - 393 *
ROMAN ET AL., EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 16, no. 4, 2006, pages S481 - S482
See also references of EP2193793A4 *
TOUNAI ET AL., METAB BRAIN DIS, vol. 22, 2007, pages 89 - 104

Also Published As

Publication number Publication date
KR101503782B1 (ko) 2015-03-18
EP2193793B1 (en) 2012-08-01
CA2701397A1 (en) 2009-04-09
PT2193793E (pt) 2012-09-28
EP2193793A4 (en) 2011-02-09
TWI432195B (zh) 2014-04-01
DK2193793T3 (da) 2012-08-20
JPWO2009044547A1 (ja) 2011-02-03
ES2389392T3 (es) 2012-10-25
CY1113364T1 (el) 2016-06-22
PL2193793T3 (pl) 2012-12-31
US7973053B2 (en) 2011-07-05
KR20100072227A (ko) 2010-06-30
EP2193793A1 (en) 2010-06-09
TW200918059A (en) 2009-05-01
US20100173938A1 (en) 2010-07-08
CN101815517A (zh) 2010-08-25
CA2701397C (en) 2015-11-03
JP5399909B2 (ja) 2014-01-29

Similar Documents

Publication Publication Date Title
HRP20130399T1 (hr) Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti
IL198411A0 (en) Haloalkylsulfonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
WO2006120176A3 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
WO2009072604A1 (ja) 抗nr10抗体、およびその利用
EP2089354A4 (en) NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING HISTONE DEACETYLASE INHIBITORY ACTIVITY AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
GB0509224D0 (en) Inhibitors of intracellular enzymatic activity
IL191542A0 (en) Use of phenyl-hydrazine- indole derivatives for the manufacture fo medicaments for modulating thrombopoietin activity
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
WO2007121125A3 (en) Hcv inhibitors
WO2006083924A8 (en) 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
WO2006075256A3 (en) 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
ZA200710414B (en) Agent for regeneration and/or protection of nerves
WO2008031817A3 (en) Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
EP1945606A4 (en) ALKYLCARBAMOYLNAPHTALENYLOXYOCTENOYLHYDROXYAMIDE DERIVATIVES HAVING HISTONE DEACETYLASE INHIBITORY ACTIVITY AND SYNTHESIS OF THE DERIVATIVES
EP4174064A4 (en) TETRAHYDROISOCINOLINE COMPOUNDS AND THEIR USE
WO2009043170A8 (en) Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
WO2008081580A1 (ja) 環状ホスファチジン酸誘導体を含む鎮痛剤
WO2008006883A3 (en) Benzopyranopyrazoles
EP2006287A4 (en) COMPOUND HAVING ANTIMALARIAL ACTIVITY AND ANTIMALARIAL DRUG CONTAINING IT AS AN ACTIVE SUBSTANCE
WO2008033389A3 (en) Macrocyclic hcv inhibitors and their uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880109935.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836702

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12676265

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008836702

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107006970

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2701397

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009535978

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE